Chronic Lymphocytic Leukemia Clinical Trials

70 studies are recruiting for chronic lymphocytic leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Banner University Medical Center - Tucson, Tucson, Arizona

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

   The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib i…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama

   Locations

   203 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06136559 on ClinicalTrials.gov

3. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

   The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St Bernards Medical Center, Jonesboro, Arkansas

   Locations

   130 in total

   Run by

   BeOne Medicines

   See if you can join NCT06846671 on ClinicalTrials.gov

4. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama At Birmingham Hospital, Birmingham, Alabama

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

5. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama At Birmingham Hospital, Birmingham, Alabama

   Locations

   214 in total

   Run by

   BeOne Medicines

   See if you can join NCT06973187 on ClinicalTrials.gov

6. A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

   The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocyti…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   114 in total

   Run by

   BeOne Medicines

   See if you can join NCT07277231 on ClinicalTrials.gov

7. Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

   This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio

   Locations

   2 in total

   Run by

   Paolo Caimi, MD

   See if you can join NCT07225439 on ClinicalTrials.gov

8. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   H. Lee Moffitt Cancer Center, Tampa, Florida

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

9. A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

   This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study interve…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Mitchell Cancer Institute, Mobile, Alabama

   Locations

   50 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07218341 on ClinicalTrials.gov

10. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

    Stage

    Not phased

    Ages

    40 to 75

    Site

    Anchorage Associates in Radiation Medicine, Anchorage, Alaska

    Locations

    745 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT05334069 on ClinicalTrials.gov

11. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhi…

    Stage

    Phase 3

    Ages

    65 and older

    Site

    University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

    Locations

    210 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT07321652 on ClinicalTrials.gov

12. Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

    The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi)…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Central Georgia Cancer Care, Macon, Georgia

    Locations

    6 in total

    Run by

    Nurix Therapeutics, Inc.

    See if you can join NCT07516093 on ClinicalTrials.gov

13. Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may st…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Kerry Rogers

    See if you can join NCT07734038 on ClinicalTrials.gov

14. Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

    The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Rocky Mountain Cancer Centers, Aurora, Colorado

    Locations

    6 in total

    Run by

    Nurix Therapeutics, Inc.

    See if you can join NCT07520006 on ClinicalTrials.gov

15. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxi…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Uci Health Laguna Hills, Laguna Hills, California

    Locations

    195 in total

    Run by

    BeOne Medicines

    See if you can join NCT06943872 on ClinicalTrials.gov

16. A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treat…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Pacific Cancer Medical Center, Inc, Anaheim, California

    Locations

    143 in total

    Run by

    Loxo Oncology, Inc.

    See if you can join NCT05254743 on ClinicalTrials.gov

17. Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    Background: The drug venetoclax treats chronic lymphocytic leukemia (CLL). Researchers want to find better treatments for CLL. To do that, they need to learn how the drug affects CLL cancer cells and the immune system. Objective: To learn about genetic changes that happen during treatment of CLL wi…

    Stage

    Phase 2

    Ages

    18 to 85

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Heart, Lung, and Blood Institute (NHLBI)

    See if you can join NCT03986034 on ClinicalTrials.gov

18. Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

    The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06849713 on ClinicalTrials.gov

19. A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

    The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    17 in total

    Run by

    BeOne Medicines

    See if you can join NCT06697184 on ClinicalTrials.gov

20. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage

    Phase 1

    Ages

    13 to 90

    Site

    City of Hope, Duarte, California

    Locations

    11 in total

    Run by

    Vironexis Biotherapeutics Inc.

    See if you can join NCT06533579 on ClinicalTrials.gov

21. A Long-term Extension Study of PCI-32765 (Ibrutinib)

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

    Locations

    175 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT01804686 on ClinicalTrials.gov

22. Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

    To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06967610 on ClinicalTrials.gov

23. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT07020533 on ClinicalTrials.gov

24. Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

    This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Roswell Park Cancer Institute, Buffalo, New York

    Run by

    Roswell Park Cancer Institute

    See if you can join NCT06863402 on ClinicalTrials.gov

25. Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

    This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Emory University Hospital Midtown, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT03501576 on ClinicalTrials.gov